RxDoctor Payments Data

Nelson Aweh, MD

Internal Medicine · Cambridge, MANPI 1891923199

Payments from drug & device makers

$140in general payments, 2019–2025

Across 2 payments — averaging $70.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$112
  • Neurocrine Biosciences, Inc.$28

What the payments were for

  • Food & beverage$140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$140 in reported general payments places this provider in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$643,777
Medicare patients
1,442
Services billed
5,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,810$481,325
XifaxanRifaximin78$120,727
Orencia ClickjectAbatacept18$107,048
XareltoRivaroxaban341$99,204
JardianceEmpagliflozin251$72,292
OrenciaAbatacept11$66,094
RexultiBrexpiprazole70$58,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$57,033
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$54,766
Lagevrio (Eua)Molnupiravir52$51,321
Invega SustennaPaliperidone Palmitate15$47,815
TrulicityDulaglutide58$43,635
AristadaAripiprazole Lauroxil16$42,500
JanuviaSitagliptin Phosphate155$41,819
Breo ElliptaFluticasone/Vilanterol94$41,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$28$38,40311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →